Articles From: Zimmer Launches a New Era in Knee Replacement with Persona™ The Personalized Knee System to ZIOPHARM Oncology Announces Initiation of Indiana University-Sponsored Phase 2 Study of Palifosfamide in Recurrent and Incurable Germ Cell (Testicular and Ovarian) Tumors


2013/3/20
Persona Knee Replacement Replicates the Anatomy and Biomechanics of the Knee for a Better Fit, More Natural Feel and More Normal Function CHICAGO , March 20, 2013 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global leader in musculoskeletal health, today introduced Persona The Personalized Knee System, at the 2013 American Academy of Orthopaedic Surgeons Annual Meeting.
Sign-up for Zimmer Launches a New Era in Knee Replacement with Persona™ The Personalized Knee System investment picks
2013/3/20
Gel-One® Offers Knee Arthritis Sufferers Pain Relief and Restored Mobility in a Single Injection CHICAGO , March 20, 2013 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a global leader in musculoskeletal health, today introduced Gel-One® Cross-linked Hyaluronate at the 2013 American Academy of Orthopaedic Surgeons Annual Meeting.
Sign-up for Zimmer Launches Single Injection Pain Relief Solution at the 2013 AAOS Annual Meeting investment picks
2013/1/31
WARSAW, Ind.
Sign-up for Zimmer Reports Fourth Quarter and 2012 Financial Results investment picks
2013/3/21
Innovative New Ankle Replacement Employs a Low Profile Design and Lateral Surgical Approach CHICAGO , March 21, 2013 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a global leader in musculoskeletal health, today introduced the Zimmer® Trabecular Metal™ Total Ankle, a complete ankle replacement and instrument system, at the 2013 American Academy of Orthopaedic Surgeons annual meeting.
Sign-up for Zimmer® Trabecular Metal™ Total Ankle Introduced at 2013 AAOS Annual Meeting investment picks
2013/2/5
New Poll Determines What Really Counts: Will Consumers Actually Buy?
Sign-up for Zimmerman Advertising's 'Z Super Poll' Finds Disney's 'Lone Ranger' The Most Effective Ad of the 2013 Super Bowl investment picks
2013/4/17
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0867481001&sourceType=1 http://www.ccnmatthews.com/logos/20080731-zinlogo.JPG VANCOUVER, BRITISH COLUMBIA --
Sign-up for Zincore Closes Loan With First Quantum Minerals investment picks
2013/4/18
DALLAS and CAESAREA, Israel, April 18, 2013 (GLOBE NEWSWIRE) -- Zion Oil & Gas, Inc. ("the Company or "Zion") (Nasdaq:ZN) announced today that, on April 16, 2013, Zion submitted to Israel's Petroleum Commissioner and other Ministry officials an application seeking a Petroleum Exploration License in the Megiddo-Jezreel Valley area, onshore Israel, covering an area of approximately 98,000 acres.
Sign-up for Zion Applies for New Exploration License in Megiddo-Jezreel Valley Area, Israel investment picks
2013/3/27
DALLAS and CAESAREA, Israel, March 27, 2013 (GLOBE NEWSWIRE) -- Zion Oil & Gas, Inc. (Nasdaq:ZN) today announced the introduction of a Dividend Reinvestment and Common Stock Purchase Plan for existing shareholders and prospective investors.
Sign-up for Zion Oil and Gas Launches Dividend Reinvestment and Direct Stock Purchase Plan investment picks
2013/4/26
SALT LAKE CITY , April 26, 2013 /PRNewswire/ -- Zions Bancorporation (Nasdaq: ZION) will hold the company's meeting of shareholders on Friday, May 24, 2013 at 1:00 p.m. MDT .
Sign-up for Zions Bancorporation Announces Annual Meeting Of Shareholders investment picks
2013/3/14
SALT LAKE CITY , March 14, 2013 /PRNewswire/ -- Zions Bancorporation (NASDAQ: ZION) ("Zions" or "the Company) today received the results of the Board of Governors of the Federal Reserve System's (FRB) review of Zions' capital plan under the FRB's 2013 Capital Plan Review.
Sign-up for Zions Bancorporation Announces Capital Plan Review Results investment picks
2013/5/13
SALT LAKE CITY , May 13, 2013 /PRNewswire/ -- Zions Bancorporation (NASDAQ: ZION) ("Zions") today announced its plans to offer $100,000,000 to $250,000,000 aggregate liquidation preference of Series I fixed/floating rate non-cumulative perpetual preferred stock pursuant to a prospectus supplement dated May 13, 2013 to its prospectus dated April 4 , 2011.
Sign-up for Zions Bancorporation Announces Plans to Auction $100 Million to $250 Million of Non-Cumulative Perpetual Preferred Stock Through Zions Direct investment picks
2013/4/26
SALT LAKE CITY , April 26, 2013 /PRNewswire/ -- Zions Bancorporation (NASDAQ:ZION) ("Zions") today announced its plans to offer 2,000,000 depositary shares ( $50,000,000 aggregate liquidation preference) to 4,000,000 depositary shares ( $100,000,000 aggregate liquidation preference) each representing a 1/40th interest in a share of Series H fixed rate non-cumulative perpetual preferred stock pursuant to a prospectus supplement dated April 22, 2013 to its prospectus dated April 4 , 2011.
Sign-up for Zions Bancorporation Announces Plans to Auction $50 Million to $100 Million of Non-Cumulative Perpetual Preferred Stock Through Zions Direct investment picks
2013/4/22
SALT LAKE CITY , April 22, 2013 /PRNewswire/ -- Zions Bancorporation ("Zions") today announced its plans to offer depositary shares each representing a 1/40th interest in a share of Series H fixed rate non-cumulative perpetual preferred stock pursuant to a previously filed prospectus supplement to its prospectus dated April 4 , 2011.
Sign-up for Zions Bancorporation Announces Plans to Auction Non-Cumulative Perpetual Preferred Stock Through Zions Direct investment picks
2013/4/2
SALT LAKE CITY , April 2, 2013 /PRNewswire/ -- Zions Bancorporation (Nasdaq: ZION) today announced that on May 3, 2013, Zions Capital Trust B will redeem all of its outstanding 8.0% capital securities (CUSIP No.
Sign-up for Zions Bancorporation Announces Redemption Of Series B Trust Preferred Securities investment picks
2013/2/28
SALT LAKE CITY , Feb.
Sign-up for Zions Bancorporation Announces Retirement Of Chief Credit Officer Ken Peterson investment picks
2013/4/29
SALT LAKE CITY , April 29, 2013 /PRNewswire/ -- Zions Bancorporation ("Zions" or the "Company") (Nasdaq: ZION) announced today that it successfully priced its offering of 5,048,846 depositary shares ( $126,221,150 aggregate liquidation preference) each representing a 1/40th interest in a share of Series H fixed rate non-cumulative perpetual preferred stock in an underwritten public transaction.
Sign-up for Zions Bancorporation Announces Successful Completion of $126.2 Million of Non-Cumulative Perpetual Preferred Stock Offering investment picks
2013/5/17
SALT LAKE CITY , May 17, 2013 /PRNewswire/ -- Zions Bancorporation ("Zions" or the "Company") (Nasdaq: ZION) announced today that it successfully priced its offering of 300,893 shares ( $300,893,000 aggregate liquidation preference) of Series I fixed/floating rate non-cumulative perpetual preferred stock in an underwritten public transaction.
Sign-up for Zions Bancorporation Announces Successful Completion of $300.9 Million of Non-Cumulative Perpetual Preferred Stock Offering investment picks
2013/4/19
SALT LAKE CITY , April 19, 2013 /PRNewswire/ -- Zions Bancorporation (NASDAQ: ZION) announced today that its board of directors declared a regular quarterly dividend on its outstanding common stock of $0.04 per common share, an increase from the previous dividend of $0.01 per common share.
Sign-up for Zions Bancorporation Board Declares Dividends For Common And Preferred Shares investment picks
2013/2/7
SALT LAKE CITY , Feb.
Sign-up for Zions Bancorporation Board Declares Dividends For Common And Preferred Shares investment picks
2013/2/7
SALT LAKE CITY , Feb.
Sign-up for Zions Bancorporation Receives Thirteen Greenwich Excellence Awards for 2012 investment picks
2013/4/22
SALT LAKE CITY , April 22, 2013 /PRNewswire/ -- Zions Bancorporation (NASDAQ: ZION) ("Zions" or "the Company") today reported first quarter net earnings applicable to common shareholders of $88.3 million or $0.48 per diluted common share, compared to $35.6 million or $0.19 per diluted share for the fourth quarter of 2012, and $25.5 million or $0.14 per diluted share for the first quarter of 2012.
Sign-up for Zions Bancorporation Reports Earnings Of $0.48 Per Diluted Common Share For First Quarter 2013 investment picks
2013/2/5
SALT LAKE CITY , Feb.
Sign-up for Zions Bancorporation To Present At The 14th Annual Credit Suisse Financial Services Forum investment picks
2013/5/14
SALT LAKE CITY , May 14, 2013 /PRNewswire/ -- Doyle L.
Sign-up for Zions Bancorporation To Present At The Barclays Americas Select Franchise Conference 2013 investment picks
2013/2/26
SALT LAKE CITY , Feb.
Sign-up for Zions Bancorporation To Present At The Citi 2013 US Financial Services Conference investment picks
2013/3/19
SALT LAKE CITY , March 19, 2013 /PRNewswire/ -- Zions Bancorporation (Nasdaq: ZION) announced today that it will report its first quarter 2013 earnings results after the NASDAQ close on Monday, April 22, 2013 .
Sign-up for Zions Bancorporation To Report First Quarter 2013 Earnings Results investment picks
2013/5/7
BOSTON, May 7, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2013, and provided an update on the Company's key developments.
Sign-up for ZIOPHARM Announces First Quarter Financial Results and Key Developments investment picks
2013/5/15
BOSTON, May 15, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Gerald P.
Sign-up for ZIOPHARM Announces Poster Presentation at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting investment picks
2013/5/16
BOSTON, May 16, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced promising results from nonclinical and Phase 1 studies in advanced melanoma using Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.
Sign-up for ZIOPHARM Announces Presentation of Promising Nonclinical and Phase I Study Results of Ad-RTS-IL-12 in Advanced Melanoma at ASGCT 16th Annual Meeting investment picks
2013/3/6
NEW YORK, March 6, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the start of a multicenter, single arm Phase 2 investigator-sponsored study of palifosfamide (ZIO-201) in patients with recurrent metastatic germ cell (testicular and ovarian) tumors who have relapsed on initial platinum-based therapy and high dose chemotherapy, or patients who are not eligible for high dose chemotherapy.
Sign-up for ZIOPHARM Oncology Announces Initiation of Indiana University-Sponsored Phase 2 Study of Palifosfamide in Recurrent and Incurable Germ Cell (Testicular and Ovarian) Tumors investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Zimmer Launches a New Era in Knee Replacement with Persona™ The Personalized Knee System to ZIOPHARM Oncology Announces Initiation of Indiana University-Sponsored Phase 2 Study of Palifosfamide in Recurrent and Incurable Germ Cell (Testicular and Ovarian) Tumors
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity